Garenoxacin to Prevent Febrile Neutropenia in Chemotherapy for Lung Cancer
Phase 2
- Conditions
- ung cancer
- Registration Number
- JPRN-UMIN000014711
- Lead Sponsor
- Institute of Biomedical Research and Innovation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Tumor fever 2)Complication such as severe infection or comobidities 3)History of severe allergic reaction 4)History of epilepsy or convulsant 5)Clinically significant heart disease 6)Uncontrolled diabetes 7)Routine use of NSAIDS 8)Routine use of steroids or immuno-suppressant 9)Chronic aspiration 10)Clinically significant psychological problems 11)unsuitable patients whom physitians consider
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method